275 related articles for article (PubMed ID: 36216488)
1. SGLT2 Inhibitors in Heart Failure: Early Initiation to Achieve Rapid Clinical Benefits.
Dixit NM; Ziaeian B; Fonarow GC
Heart Fail Clin; 2022 Oct; 18(4):587-596. PubMed ID: 36216488
[TBL] [Abstract][Full Text] [Related]
2. Impact of Inpatient Initiation of Sodium-Glucose Cotransporter-2 Inhibitors on Prescription Rates in Patients With Heart Failure With Reduced Ejection Fraction.
Okoroike H; Patel S; Simone P; Lavelle R; Szwak JA
Am J Cardiol; 2023 Jan; 186():150-155. PubMed ID: 36283884
[TBL] [Abstract][Full Text] [Related]
3. Impact of SGLT2 inhibitors on cardiovascular outcomes in patients with heart failure with reduced ejection fraction.
Starr JA; Pinner NA; Lisenby KM; Osmonson A
Pharmacotherapy; 2021 Jun; 41(6):526-536. PubMed ID: 33866578
[TBL] [Abstract][Full Text] [Related]
4. Prescription Patterns of Sodium-Glucose Cotransporter 2 Inhibitors and Cardiovascular Outcomes in Patients with Diabetes Mellitus and Heart Failure.
Hofer F; Kazem N; Richter B; Sulzgruber P; Schweitzer R; Pailer U; Hammer A; Koller L; Hengstenberg C; Niessner A
Cardiovasc Drugs Ther; 2022 Jun; 36(3):497-504. PubMed ID: 34342791
[TBL] [Abstract][Full Text] [Related]
5. Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure.
Shah KS; Fang JC
Annu Rev Pharmacol Toxicol; 2022 Jan; 62():109-120. PubMed ID: 34516288
[TBL] [Abstract][Full Text] [Related]
6. SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: A Paradigm Shift Toward Dual Cardio-Renal Protection.
Rastogi T; Girerd N
Heart Fail Clin; 2022 Oct; 18(4):561-577. PubMed ID: 36216486
[TBL] [Abstract][Full Text] [Related]
7. Sodium-Glucose Cotransporter 2 Inhibitors First Strategy Improve Decongestion in Patients with Symptomatic Heart Failure and Reduced Ejection Fraction When Compared to Angiotensin Receptor Neprilysin Inhibitor First Strategy.
Lee WC; Chang WT; Hong CS; Liao CT; Huang PS; Huang SC; Lin CH; Chiang CY; Chen ZC; Shih JY
Front Biosci (Landmark Ed); 2023 Apr; 28(4):81. PubMed ID: 37114551
[TBL] [Abstract][Full Text] [Related]
8. Impact of Sodium-Glucose Cotransporter-2 Inhibitors on Cardiac Bioenergetic Properties and Cardiorespiratory Fitness: A Special Effect of SGLT2i In Heart Failure?
Farooq M; Jorde UP
Cardiol Rev; 2023 Mar-Apr 01; 31(2):65-69. PubMed ID: 35191660
[TBL] [Abstract][Full Text] [Related]
9. Pharmacologic Therapy for Heart Failure with Preserved Ejection Fraction.
Peters AE; DeVore AD
Cardiol Clin; 2022 Nov; 40(4):473-489. PubMed ID: 36210132
[TBL] [Abstract][Full Text] [Related]
10. Optimal Pharmacologic Treatment of Heart Failure With Preserved and Mildly Reduced Ejection Fraction: A Meta-analysis.
Xiang B; Zhang R; Wu X; Zhou X
JAMA Netw Open; 2022 Sep; 5(9):e2231963. PubMed ID: 36125813
[TBL] [Abstract][Full Text] [Related]
11. [ANMCO practical guide for sodium-glucose cotransporter 2 inhibitor use in patients with heart failure].
Di Fusco SA; Spinelli A; Aquilani S; Gulizia MM; Gabrielli D; Oliva F; Colivicchi F
G Ital Cardiol (Rome); 2023 Jan; 24(1):66-74. PubMed ID: 36573513
[TBL] [Abstract][Full Text] [Related]
12. SGLT2 Inhibitors and Heart Failure with Preserved Ejection Fraction.
Jhund PS
Heart Fail Clin; 2022 Oct; 18(4):579-586. PubMed ID: 36216487
[TBL] [Abstract][Full Text] [Related]
13. Different effects of SGLT2 inhibitors according to the presence and types of heart failure in type 2 diabetic patients.
Hwang IC; Cho GY; Yoon YE; Park JJ; Park JB; Lee SP; Kim HK; Kim YJ; Sohn DW
Cardiovasc Diabetol; 2020 May; 19(1):69. PubMed ID: 32466760
[TBL] [Abstract][Full Text] [Related]
14. SGLT2 inhibitors: What role do they play in heart failure with reduced ejection fraction?
Lenahan CM; Harrington D; Stueben F
Nurse Pract; 2021 Jul; 46(7):30-37. PubMed ID: 34138811
[TBL] [Abstract][Full Text] [Related]
15. Chapter 2: Clinical and Mechanistic Potential of Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors in Heart Failure with Preserved Ejection Fraction.
Ostrominski JW; Vaduganathan M
Am J Med; 2024 Feb; 137(2S):S9-S24. PubMed ID: 37160196
[TBL] [Abstract][Full Text] [Related]
16. Heart Failure with Preserved Ejection Fraction and Obstructive Sleep Apnea: A Novel Paradigm for Additional Cardiovascular Benefit of SGLT2 Inhibitors in Subjects With or Without Type 2 Diabetes.
Monda VM; Gentile S; Porcellati F; Satta E; Fucili A; Monesi M; Strollo F
Adv Ther; 2022 Nov; 39(11):4837-4846. PubMed ID: 36112311
[TBL] [Abstract][Full Text] [Related]
17. SGLT2i in heart failure: can their benefits be expanded across the entire spectrum of ejection fraction?
Requena-Ibáñez JA; Santos-Gallego CG; Badimón JJ
Rev Esp Cardiol (Engl Ed); 2022 Oct; 75(10):833-841. PubMed ID: 35817327
[TBL] [Abstract][Full Text] [Related]
18. Growing role of SGLT2i in heart failure: evidence from clinical trials.
Varadhan A; Stephan K; Gupta R; Vyas AV; Ranchal P; Aronow WS; Hawwa N; Lanier GM
Expert Rev Clin Pharmacol; 2022 Feb; 15(2):147-159. PubMed ID: 35264076
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular outcomes with SGLT2 inhibitors versus DPP4 inhibitors and GLP-1 receptor agonists in patients with heart failure with reduced and preserved ejection fraction.
Gonzalez J; Bates BA; Setoguchi S; Gerhard T; Dave CV
Cardiovasc Diabetol; 2023 Mar; 22(1):54. PubMed ID: 36899387
[TBL] [Abstract][Full Text] [Related]
20. Sodium-glucose co-transporter 2 inhibitors in acute heart failure: real-world prescription trends and outcomes analysis.
Mizobuchi S; Saito Y; Kitano D; Toyama K; Miyagawa M; Koyama Y; Fujito H; Kojima K; Murata N; Fukamachi D; Okumura Y
ESC Heart Fail; 2024 Feb; 11(1):410-421. PubMed ID: 38017700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]